文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

香港奥密克戎波期间社区门诊确诊SARS-CoV-2感染者使用莫诺拉韦与奈玛特韦联合利托那韦的真实世界有效性:观察性研究

Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
PubMed 文献 · Lancet · 2022-01-01
一句话结论香港奥密克戎BA.2.2波期间,社区非住院COVID-19患者早期使用莫诺拉韦或奈玛特韦联合利托那韦与死亡及院内疾病进展风险降低相关,奈玛特韦联合利托那韦还与住院风险降低相关。

该观察性研究利用香港医院管理局数据,纳入2022年2月26日至6月26日奥密克戎BA.2.2优势期间全港非住院SARS-CoV-2感染者1 074 856例,其中社区使用莫诺拉韦5383例、奈玛特韦联合利托那韦6464例,按倾向评分1:10匹配对照。莫诺拉韦与死亡风险降低(HR 0.76,95%CI 0.61-0.95)和院内疾病进展风险降低(HR 0.57,95%CI 0.43-0.76)相关,住院风险相似(HR 0.98,95%CI 0.89-1.06);奈玛特韦联合利托那韦与死亡(HR 0.34,95%CI 0.22-0.52)、住院(HR 0.76,95%CI 0.67-0.86)和院内疾病进展(HR 0.57,95%CI 0.38-0.87)风险降低相关。在老年患者中一致发现早期口服抗病毒药与死亡和住院风险降低相关。

要点

  • 社区非住院COVID-19患者使用奈玛特韦联合利托那韦与死亡风险降低相关(HR 0.34,95%CI 0.22-0.52)、住院风险降低(HR 0.76,95%CI 0.67-0.86)和院内疾病进展风险降低(HR 0.57,95%CI 0.38-0.87)。
  • 社区非住院COVID-19患者使用莫诺拉韦与死亡风险降低相关(HR 0.76,95%CI 0.61-0.95)和院内疾病进展风险降低(HR 0.57,95%CI 0.43-0.76),但与住院风险相似(HR 0.98,95%CI 0.89-1.06)。
  • 在老年患者中一致发现早期口服抗病毒药与死亡和住院风险降低相关。
  • 莫诺拉韦组患者较奈玛特韦联合利托那韦组年龄更大(>60岁:4758/5383 [85.9%] vs 4418/6464 [88.7%])且完全接种疫苗比例更低(1850/5383 [33.4%] vs 800/6464 [16.1%])。

适用人群与场景

  • 香港全港非住院、社区居住、官方登记确诊SARS-CoV-2感染的患者,年龄、性别、诊断日期、Charlson合并症指数评分和疫苗接种状态经倾向评分1:10匹配。
  • 研究期间为2022年2月26日至6月26日,奥密克戎BA.2.2亚型优势期。

处置流程与药物剂量

  • 莫诺拉韦:800 mg,每日两次,口服,疗程5天。
  • 奈玛特韦联合利托那韦:奈玛特韦300 mg联合利托那韦100 mg,每日两次,口服,疗程5天;若估算肾小球滤过率30-59 mL/min每1.73 m2,则奈玛特韦150 mg联合利托那韦100 mg,每日两次,口服,疗程5天。

研究设计与关键结果

  • 研究类型:观察性研究,主要分析为回顾性队列设计,敏感性分析为病例对照设计;数据来自香港医院管理局,纳入1 074 856例非住院COVID-19患者。
  • 社区使用莫诺拉韦5383例,奈玛特韦联合利托那韦6464例;莫诺拉韦组中位随访103天,奈玛特韦联合利托那韦组中位随访99天。
  • 与未使用相比,莫诺拉韦使用与死亡风险降低相关(HR 0.76 [95%CI 0.61-0.95])、院内疾病进展风险降低相关(HR 0.57 [95%CI 0.43-0.76]),住院风险相似(HR 0.98 [95%CI 0.89-1.06])。
  • 与未使用相比,奈玛特韦联合利托那韦使用与死亡风险降低相关(HR 0.34 [95%CI 0.22-0.52])、住院风险降低相关(HR 0.76 [95%CI 0.67-0.86])和院内疾病进展风险降低相关(HR 0.57 [95%CI 0.38-0.87])。
  • 在老年患者中一致发现早期口服抗病毒药与死亡和住院风险降低相关。
  • 病例对照敏感性分析结果与主要分析大体一致。

证据类型、等级与局限

  • 证据类型:观察性研究(回顾性队列为主要分析,病例对照为敏感性分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在奥密克戎BA.2.2优势期间,对社区非住院COVID-19患者早期启动莫诺拉韦或奈玛特韦联合利托那韦与死亡和院内疾病进展风险降低相关;奈玛特韦联合利托那韦还与住院风险降低相关(作者结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Little is known about the real-world effectiveness of oral antivirals against the SARS-CoV-2 omicron (B.1.1.529) variant. We aimed to assess the clinical effectiveness of two oral antiviral drugs among community-dwelling COVID-19 outpatients in Hong Kong.

METHODS: In this observational study, we used data from the Hong Kong Hospital Authority to identify an unselected, territory-wide cohort of non-hospitalised patients with an officially registered diagnosis of SARS-CoV-2 infection between Feb 26 and June 26, 2022, during the period in which the omicron subvariant BA.2.2 was dominant in Hong Kong. We used a retrospective cohort design as primary analysis, and a case-control design as sensitivity analysis. We identified patients with COVID-19 who received either molnupiravir (800 mg twice daily for 5 days) or nirmatrelvir plus ritonavir (nirmatrelvir 300 mg and ritonavir 100 mg twice daily for 5 days, or nirmatrelvir 150 mg and ritonavir 100 mg if estimated glomerular filtration rate was 30-59 mL/min per 1·73 m2). Outpatient oral antiviral users were matched with controls using propensity score (1:10) according to age, sex, date of SARS-CoV-2 infection diagnosis, Charlson Comorbidity Index score, and vaccination status. Study outcomes were death, COVID-19-related hospitalisation, and in-hospital disease progression (in-hospital death, invasive mechanical ventilation, or intensive care unit admission). Hazard ratios (HRs) were estimated by Cox regression for the primary analysis, and odds ratios in oral antiviral users compared with non-users by logistic regression for the sensitivity analysis.

FINDINGS: Among 1 074 856 non-hospitalised patients with COVID-19, 5383 received molnupiravir and 6464 received nirmatrelvir plus ritonavir in the community setting. Patients were followed up for a median of 103 days in the molnupiravir group and 99 days in the nirmatrelvir plus ritonavir group. Compared with nirmatrelvir plus ritonavir users, those on molnupiravir were older (4758 [85·9%] vs 4418 [88.7%] aged >60 years) and less likely to have been fully vaccinated (1850 [33·4%] vs 800 [16·1%]). Molnupiravir use was associated with lower risks of death (HR 0·76 [95% CI 0·61-0·95]) and in-hospital disease progression (0·57 [0·43-0·76]) than non-use was, whereas risk of hospitalisation was similar in both groups (0·98 [0·89-1·06]). Nirmatrelvir plus ritonavir use was associated with lower risks of death (0·34 [0·22-0·52]), hospitalisation (0·76 [0·67-0·86]), and in-hospital disease progression (0·57 [0·38-0·87]) than non-use was. We consistently found reduced risks of mortality and hospitalisation associated with early oral antiviral use among older patients. The findings from the case-control analysis broadly supported those from the primary analysis.

INTERPRETATION: During Hong Kong's wave of SARS-CoV-2 omicron subvariant BA.2.2, among non-hospitalised patients with COVID-19, early initiation of novel oral antivirals was associated with reduced risks of mortality and in-hospital disease progression. Nirmatrelvir plus ritonavir use was additionally associated with a reduced risk of hospitalisation.

FUNDING: Health and Medical Research Fund, Health Bureau, Government of Hong Kong Special Administrative Region, China.

TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022. PMID: 36216007. doi:10.1016/S0140-6736(22)01586-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。